Allied Biotech Corporation

TPEX:1780 Stock Report

Market Cap: NT$1.6b

Allied Biotech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Allied Biotech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth49.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Is Allied Biotech Corporation (GTSM:1780) A Good Dividend Stock?

Apr 16
Is Allied Biotech Corporation (GTSM:1780) A Good Dividend Stock?

These 4 Measures Indicate That Allied Biotech (GTSM:1780) Is Using Debt Reasonably Well

Mar 05
These 4 Measures Indicate That Allied Biotech (GTSM:1780) Is Using Debt Reasonably Well

Allied Biotech (GTSM:1780) Has Compensated Shareholders With A Respectable 49% Return On Their Investment

Jan 24
Allied Biotech (GTSM:1780) Has Compensated Shareholders With A Respectable 49% Return On Their Investment

Is Allied Biotech Corporation (GTSM:1780) At Risk Of Cutting Its Dividend?

Jan 03
Is Allied Biotech Corporation (GTSM:1780) At Risk Of Cutting Its Dividend?

A Look At The Intrinsic Value Of Allied Biotech Corporation (GTSM:1780)

Dec 13
A Look At The Intrinsic Value Of Allied Biotech Corporation (GTSM:1780)

Is Allied Biotech (GTSM:1780) A Risky Investment?

Nov 25
Is Allied Biotech (GTSM:1780) A Risky Investment?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Allied Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:1780 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024769106183213N/A
3/31/2024745102136176N/A
12/31/20237209790138N/A
9/30/2023728121112161N/A
6/30/2023736144134183N/A
3/31/2023727145122174N/A
12/31/2022717147110164N/A
9/30/202269910557113N/A
6/30/202268162561N/A
3/31/2022679381467N/A
12/31/2021677132272N/A
9/30/2021658322275N/A
6/30/2021639512177N/A
3/31/2021629651268N/A
12/31/202061879359N/A
9/30/202061372763N/A
6/30/2020608651267N/A
3/31/2020624864392N/A
12/31/201963910774116N/A
9/30/2019670120106145N/A
6/30/2019700134139173N/A
3/31/2019728138150186N/A
12/31/2018765133116160N/A
9/30/201876412486145N/A
6/30/201876311456130N/A
3/31/201871599N/A103N/A
12/31/201768271N/A100N/A
9/30/201764553N/A107N/A
6/30/201760935N/A113N/A
3/31/201760329N/A113N/A
12/31/201657440N/A127N/A
9/30/201656354N/A126N/A
6/30/201655268N/A126N/A
3/31/201653857N/A114N/A
12/31/201552446N/A102N/A
9/30/201551630N/AN/AN/A
6/30/201550913N/A53N/A
3/31/201549210N/A30N/A
12/31/20144747N/A8N/A
9/30/201448811N/AN/AN/A
6/30/201450215N/A4N/A
3/31/201449111N/A34N/A
12/31/20134806N/A65N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1780's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 1780's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 1780's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1780's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 1780's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1780's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y